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Abstract
Background: Hyperandrogenism and insulin resistance may be related to the etiology of PCOS. Zucker fa/fa rats
with polycystic ovary are obese, have insulin resistance without diabetes mellitus or hyperandrogenism and can be
utilized as PCOS model rats without effects of hyperandrogenemia. PCOS patients are reported to have elevated
levels of serum anti-Mullerian hormone (AMH), which has an inhibitory action on folliculogenesis, and low levels of
serum adiponectin, which blocks apoptosis and induces biological effects in some tissues. Pioglitazone, an insulin
sensitizer, is administered to PCOS patients with insulin resistance to induce ovulation but the mechanisms by
which this occurs have not been elucidated.
Methods: We purchased 4-week-old female fatty Zucker fa/fa rats as well as lean Zucker +/+ rats for use as control
rats with normal insulin sensitivity. The Zucker fa/fa rats were administered pioglitazone (2.5 mg/kg body weight/
day) or a vehicle every day for 14 days in separate groups. The Zucker +/+ rats were also administered the vehicle.
After 2 weeks of treatment, they were euthanized and we obtained serum samples and both ovaries and
determined the body weight, ovarian weight, and serum AMH, adiponectin, testosterone, and androstenedione
levels. We also examined ovarian histology to check follicle numbers by using hematoxylin-eosin staining, and the
number of atretic follicles using Tdt-mediated dUTP nick end labeling (TUNEL) methods.
Results: The Zucker fa/fa rats used as PCO model rats and Pioglitazone treated PCO model rats were significantly
heavier than the Zucker +/+ control rats (p < 0.05) at 15 day old. Pioglitazone treatment did not influence body
weight or ovarian weight in either group. However, the total number of follicles was significantly larger in the PCO
model rats than in the control rats (P < 0.05).
Although pioglitazone treatment appeared to decrease the total number of follicles in the PCO model rats, the
decrease was not statistically significant. However, pioglitazone treatment significantly decreased the total number
of atretic follicles and the rate of atreteic follicles in the PCO model rats (P < 0.05). The serum AMH level was
significantly higher in the PCO model rats than in the control rats. Pioglitazone treatment significantly decreased
the serum AMH level and significantly increased the serum adiponectin level in the PCO model rats (P < 0.05).
Serum testosterone and androstenedione levels were quite low or undetectable in the 3 groups of rats, and were
not influenced by pioglitazone treatment.
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Conclusion: In this study, pioglitazone treatment reduced the serum AMH level and increased the serum
adiponectin level in PCO model rats. These effects are related to reduction of the total number of atretic follicles
and rate of atretic follicles. This proves that pioglitazone treatment improves healthy follicle growth in these PCO
model rats with insulin resistance.
Keywords: PCOS, Polycystic ovary syndrome, PCO, Polycystic ovary, Zucker fa/fa rat, Insulin resistance, Atretic
follicle, Pioglitazone, Insulin sensitizer, AMH, Adiponectin
Background
PCOS patients are well known to frequently have insulin
resistance. However, it is unknown by what mechanisms
insulin resistance induces the pathophysiological condi-
tion of PCOS. Thus we need a rat PCOS model with in-
sulin resistance to study their precise relationship.
Zucker fatty (fa/fa) rats are a well-understood model of
obesity and hyperinsulinemia, which arise when the ani-
mals are about 4 weeks of age and gradually worsen
thereafter. The cause of the obesity is overeating induced
by a loss of leptin signaling associated with a leptin re-
ceptor mutation. Recently we proposed these rats as a
PCOS model with insulin resistance [1]. These PCO
model rats have a higher number follicles than the lean
Zucker (+/+) rats used as controls. They also have a
higher rate of atretic follicles than the control rats. How-
ever, serum androgens are almost undetectable in these
rats. Thus, this PCOS model is created by insulin resist-
ance rather than by elevated androgens.
Clinically, insulin sensitizers are often reported to in-
duce ovulation in PCOS patients with anovulation. Pioglit-
azone is a thiazolidine derivative that is used for the
treatment of type 2 diabetes mellitus. It decreases periph-
eral insulin resistance via the peroxisome proliferator-
activated receptor-γ (PPAR-γ) pathway [2]. Several studies
have demonstrated that it improves the clinical, hormonal,
and metabolic status in patient with PCOS [3–6]. More-
over, this drug directly inhibits estradiol and testosterone
production in human ovarian cells in vitro [7]. Pioglita-
zone counteracts the tumor necrosis factor-α inhibition of
FSH-induced follicular development and steroidogenesis
in an in vitro mouse preantral follicle culture system [3],
and pioglitazone–induced reduction in peripheral insulin
resistance and its direct effect on the ovaries might be ef-
fective for inducing ovulation in patients with PCOS. A
meta-analysis of comparisons of the effects of pioglitazone
and metformin in treating patients with PCOS proved that
pioglitazone improved the menstrual cycle and ovulation
better than metformin [8]. However, the mechanism by
which it ameliorates the pathophysiological conditions of
PCOS is still unknown.
There are some important serum markers that indicate
the status of PCOS such as adiponectin and AMH. Adi-
ponectin is a 30-kDa protein comprised of 247 amino
acids in four domains and has been shown to possess
insulin-sensitizing [9–11], anti-atherogenic [12, 13] and
anti-inflamatory properties [14]. It also reportedly in-
hibits apoptosis of endothelial cells [15]. Zucker fa/fa
rats have a higher serum adiponectin level than lean rats
[16]. Adiponectin and its receptors are expressed in the
rat testis [17] and ovary [18, 19] and play a significant
role in steroidogenesis [20], but the mechanism under-
lying the changes in ovarian adiponectin expression
caused by obesity/insulin resistance remains unknown.
Adiponectin has the ability to stimulate insulin sensitiv-
ity in many tissues. Although it has multiple biological
activities, it was long unclear what effects it had on ovar-
ian function. However, our previous study showed that
an abrupt reduction in serum adiponectin appeared to
be correlated with acceleration of follicular atresia with
aging in mature Zucker fa/fa rats [1].
AMH is also well known to be a Mullerian-inhibiting
substance, and it is significantly elevated in the sera of
PCOS patients compared to healthy women. AMH has
an inhibitory role in the ovary, reducing both primordial
follicle initiation and follicle sensitivity to FSH via inhib-
ition of aromatase. Interestingly, Pellatt et al. [21] men-
tioned in their review article that the reason for the
raised AMH level in PCOS might give clues as to the
mechanism of anovulation. AMH appears to have a
major inhibitory role during folliculogenesis, which may
contribute to anovulation in PCOS patients. Therefore
we need to clarify the mechanisms by which pioglitazone
improves the pathophysiological condition of PCOS
using PCO model rats with insulin resistance.
Methods
Animal treatments and tissue collection
Animals used in this study were maintained in accord-
ance with the guidelines of the Animal Resources Center
of the Sapporo Medical University School of Medicine
and the Japan SLC Laboratory Animal Care and Use
Committee (D55–0215). Female fatty Zucker fa/fa rats
with insulin resistance [22] and lean Zucker +/+ rats
with normal insulin sensitivity 4 weeks of age were pur-
chased from the Japan SLC (Shizuoka, Japan).
We administered pioglitazone (2.5 mg/ml in 0.5% me-
thyl cellulose/kg body weight/day) to Zucker fa/fa rats
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or a vehicle (0.5% methyl cellulose) to Zucker fa/fa rats
and Zucker +/+ rats every day for 14 days. After 2 weeks
of treatment, the rats were killed and we obtained serum
samples and both ovaries. We determined the body
weight, ovarian weight, and serum AMH (CLEIA
method), adiponectin (latex turbidimetric immunoassay),
testosterone (ECLIA method), and androstenedione
(RIA precipitation method) levels. We also examined
ovarian histology to check follicle numbers by using
hematoxylin-eosin staining. Each groups had 5 rats, and
totally 15 individual animal were used.
Tdt-mediated dUTP nick end labeling (TUNEL) methods
for atretic follicles
TUNEL was carried out using an ApopTag Plus Peroxid-
ase In Situ Apoptosis Detection Kit (Intergen, NY) as
described previously [1]. Tissue samples embedded in
paraffin were cut into 5-μm-thick sections, which were
then deparaffinized in xylene and rehydrated through a
graded ethanol series in distilled water. Each section was
first incubated with proteinase K, after which endogen-
ous peroxidase activity was removed by treatment with
0.3% H2O2 for 20 min at room temperature. After in-
tense washing with distilled water for 15 min, the sec-
tions were soaked in TdT buffer for 15 min, and then
incubated for 60 min at room temperature in TdT buffer
containing biotin. The bionylated dUTP incorporated
into the nuclear DNA was reacted with HRP-conjugated
streptavidin (1:100 dilution) for 30 min at room
temperature, after which the color was developed by im-
mersing the sections for 10 min in 50 mmol/l Tris-HCl
buffer (pH 7.6) containing 0.3 mg/ml DAB, 10 mmol
imidazole and 0.003% H2O2. Finally, the sections were
counterstained with hematoxylin. Negative controls were
reacted in parallel with the omission of the terminal
trasferase. For TUNEL assay 2 sections of ovarium were
examined from each animals.
Statistics
Data were analyzed using StatView (Version 4, Abacus
Concepts). Quantitative data are presented as mean ±
SD. For these experiments, we used two or three
groups and made measurements at several different
time points. We examined the data of three groups by
statistical analysis using Student-Newman-Keuls
method or we did a point-by-point comparison between
two groups using Mann-Whitney’s test. Values of P <
0.05 were considered significant.
Results
Body weight and ovarian weight
The body weights of both PCO model rats and
pioglitazone-treated PCO model rats were significantly
heavier than for control rats at day 15. There was no
significant difference of body weight between the PCO
model rats and piogtlitazone-treated PCOmodel rats (Fig. 1).
Ovarian weights of the three groups did not differ (Fig. 2).
Atretic follicles of ovaries in PCO model rats and
pioglitazone-treated rats
Figure 3a, b and c show representative sections of folli-
cles from the ovaries of rats in the control, PCO model
and pioglitazone-treated PCO model rat, respectively.
The total number (123.40 ± 11.52) of follicles including
preantral follicles and small antral follicles in PCO
model rats was significantly larger than in the control
rats (90.80 ± 14.50) (p < 0.05) as in our previous paper
[1]. The total number (100.50 ± 19.95) of follicles of
pioglitazone-treated PCO model rats appeared to be
lower than in the PCO model rats, but the difference
was not significant.
The rates of primodial follicles, primary follicles, and
preantral/small antral follicles are generally 15, 20 and
50%, respectively, in all 3 groups. The rate of preovula-
tory follicles including follicular cysts and corpora lutea
was generally less than 15% in all 3 groups. Pioglitazone
treatment did not alter the population in any develop-
mental stage of follicles. This prompted us to carry out
TUNEL analysis of the follicles and to classify them as
atretic if they had five or more apoptic granulosa cells
[23]. We found TUNEL-positive cells scattered among
the granulosa cells within atretic follicles in both the
PCO model rats and control rats; however, the number
(65.40 ± 8.65) and rate (52.99 ± 2.85%) of TUNEL-
positivity were significantly higher in the small antral/
preantral follicles of the PCO model rats than in those
(37.25 ± 6.61, 41.19 ± 3.21%) of the control rats (P <
0.05). The number and rate of TUNEL-positivity of
pioglitazone-treated PCO model rats (44.25 ± 10.28,
43.82 ± 2.78%) were significantly lower than those of the
PCO model rats(P < 0.05) (Table 1).
Hormone profiles of PCO model rats and pioglitazone-
treated rats
Serum androgens (testosterone and androstenedione)
were measured in all 3 groups. However, these andro-
gens were almost under detectable in all 3 groups. The
serum AMH levels of PCO model rats were significantly
elevated compared to control rats. However, the serum
AMH level in pioglitazone-treated PCO model rats was
significantly lower than in the vehicle-treated PCO
model rats (Fig. 4).The serum adiponectin level in PCO
model rats was significantly higher than that in control
rats. Moreover, the serum adiponectin level in
pioglitazone-treated PCO model rats was significantly
higher than in vehicle-treated PCO model rats (Fig. 5).
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Fig. 1 Body weights of control rats (Zucker +/+ rats), PCO model rats (Zucker fa/fa rats) and pitoglitazone-treated PCO model rats, Body weights of
these rats were examined every day from day 1(the day pioglitazone injection started) through day 15 (the day the rats were killed). Ovarian weights
of these rats were examined on day 15. The weight of PCO model rats and Pioglitazone treated PCO rats model were significantly heavier than that of
control rats at day 15. Values are means±SD, *P < 0.05 v.s. PCO model rats, Pioglitazone-treated PCO model rats
Fig. 2 Ovarian weights of control rats (Zucker +/+ rats), PCO model rats (Zucker fa/fa rats) and pitoglitazone-treated PCO model rats. Both ovarian
weights of the three groups did not differ. Values are means±SD
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Discussion
Our PCO model rats (Zucker fa/fa rats) had a higher
number of follicles than the lean Zucker (+/+) rats used as
controls, as well as a higher rate of atretic follicles than
the control rats. The PCO model rats also had a higher
serum AMH level than the control rats as AMH is corre-
lated with the number of follicles. Pioglitazone, which is a
selective synthetic agonist of PPAR-gamma, is well known
to improve the menstrual cycle and ovulation [8], In this
study, pioglitazone treatment reduced the total number
and rate of atretic follicles in PCO model rats. Pioglita-
zone treatment in this rat model also increased the serum
adiponectin level. As adiponectin is reported to ameliorate
reduced insulin receptor expression and reduce androgen
synthesis in ovaries in PCOS [24], the elevated adiponec-
tin level induced by pioglitazone treatment in these model
rats possibly ameliorated the pathophysiological status. Pi-
oglitazone treatment also reduced the serum AMH level
in the PCO model rats. AMH is speculated to have an in-
hibitory effect on folliclogenesis in the anovulaton in
PCOS. Thus pioglitazone has significant actions on mul-
tiple phenotypes of PCO model rats [21]. These results
show that pioglitazone might ameliorate the pathophysio-
logical status of PCOS via these multiple actions demon-
strated in this study.
PCOS is the commonest endocrine disorder in women,
affecting 5–10% of females of reproductive age [25], who
account for 30–60% of anovulatory infertility patients. Its
basic characteristics are hyperandrogenism, chronic
anovulation and polycystic ovaries. Patients very often
have insulin resistance, central obesity, impaired glucose
tolerance, dyslipidemia, cardiovascular risk and subclinical
atherosclerosis [8]. Thiazolines (TZDs) are highly selective
synthetic agonists of PPAR-γ used for the treatment of
diabetes. The classical insulin sensitizers include troglita-
zone, rosiglitazone and pioglitazone. The pathogenesis of
PCOS may be related to alteration of the PPAR-γ gene,
and PPAR-γ seems to play an important role in fertility
and metabolism through the effects of its different hypo-
types. For example, PPAR-γ can regulate ovarian function
[26]. Insulin resistance is an important aspect of PCOS
and has been observed not only in obese, but also in lean
women with PCOS and seems to be an intrinsic part of
the syndrome [27, 28]. PPAR-γ agonists can decrease an-
drogen synthesis in ovaries by ameliorating peripheral in-
sulin resistance indirectly [29]. Thus, there are theoretical
and practical bases for the treatment of PCOS with TDZ
therapy. The treatment of PCOS with TDZs has been in-
vestigated in many animal and clinical studies and trials,
and most of the trials showed effective therapeutic results.
However, a clear evidence-based explanation of the mech-
anism by which this occurs is still lacking. In this study,
pioglitazone clearly reduced the total number and rate of
atretic follicles in PCO model rats, although these effects
have not so far been clear in human patients with PCOS.
The finding that pioglitazone also reduced serum AMH
levels in the PCO rat model supports the above
phenomena.
a b c
Fig. 3 Ovarian histology of atretic follicles detected by the TUNEL method, and total follicle numbers, atretic follicle numbers and rates of atretic
follicles of control rats (Zucker +/+ rats), PCO model rats (Zucker fa/fa rats) and pitoglitazone-treated PCO model rats. The TUNEL method and follicle
counts of these rats were performed on day 15 in control rats (a), PCO model rats (b) and Pioglitazone treated PCO model rats (c) (the day the rats
were killed). Follicles were classified as atretic ▲ if they had five or more apoptic granulosa cells [23]. Values are means±SD, *P < 0.05 v.s. control rats.
**P, 0.05 v.s. control rats, Pioglitazone treated PCO model rats
Table 1 Total follicle number, atretic follicle number and rate of atretic follicles
Number or percent Control rats PCO model rats Pioglitazone treated PCO model rats
Total follicle number 90.80 ± 14.50 123.40 ± 11.52* 100.50 ± 19.95
Atretic follicle number 37.25 ± 6.61 65.40 ± 8.65** 44.25 ± 10.28
Rate of atretic follicle (%) 41.19 ± 3.21% 52.99 ± 2.85%** 43.82 ± 2.78%
Number of rats 5 5 5
Values are mean ± SD
*P < 0.05 v.s. control rats
**P < 0.05 v.s. control rats, Pioglitazone treated PCO model rats
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AMH has curious activity in folliculogenesis. Pellatt et
al. mentioned in their review article that over the last dec-
ade, a new and interesting role has emerged for AMH in
the ovary. In human ovaries, AMH is produced by granu-
losa cells from 36 weeks of gestation until menopause,
with the highest expression being in small antral follicles.
The AMH production gradually declines as the follicles
grow, and once they reach a size at which they are domin-
ant, it has largely disappeared. Its removal from these lar-
ger follicles appears to be an important requirement for
dominant follicle selection and progression to ovulation as
AMH has an inhibitory role in the ovary, reducing both
primodial follicle initiation and follicle sensitivity to FSH
via inhibition of aromatase [21]. Understanding the reason
for the elevated AMH level in PCOS may thus give us an
idea of the mechanism of anovulation since AMH appears
to have a major inhibitory role during folliculogenesis,
which may contribute to anovulation. The effects of pio-
glitazone treatment in this study provide clues to the
mechanisms of pioglitazone treatment for ovulation in the
anovulatory status of PCOS via reduction of the high level
of serum AMH.
Fig. 4 Serum AMH levels of control rats (Zucker +/+ rats), PCO model rats (Zucker fa/fa rats) and pitoglitazone-treated PCO model rats. Serum
AMH levels were measured on day 15 (the day the rats were killed). Values are means±SD, *P < 0.05
Fig. 5 Serum adiponectin levels of control rats (Zucker +/+ rats), PCO model rats (Zucker fa/fa rats) and pitoglitazone-treated PCO model rats.
Serum adiponectin levels were measured in these rats on day 15 after fasting the rats for 12 h. Values are means±SD, *P < 0.05
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Adiponectin is an adipocytocine that may act in
reproduction. Serum adiponectin levels in human PCOS
were found to be significantly lower than in controls,
suggesting a role for adiponectin in the pathogenesis of
the syndrome [30–32]. Adiponectin has several actions
in reproduction. It is reported to significantly increase
the expression of ovulation-related genes and enhances
FSH-mediated induction of Areg, Has2 and Ptgs2, indi-
cating the selective responses of cumulus cells to adipo-
nectin [33]. In cultured theca cells, adiponectin
suppresses androstenedione production and gene ex-
pression of LH receptors and key enzymes in the andro-
gen synthesis pathway. Moreover, knockdown of genes
for AdpoR1 and AdipoR2 is associated with increased
androstenedione secretion by bovine theca cells. These
results provide evidence for a direct link between fat cell
metabolism and ovarian steroidogenesis, suggesting that
disruption of adiponectin and/or its receptors plays a
key role in the pathogenesis of hyperandrogenenism in
PCOS [25]. Recently it was reported that treatment with
adiponectin directly ameliorated hyprandrogenemia and
increased insulin receptor expression in a PCO-mouse
culture experiment [24]. It was also reported that sys-
temic adiponectin treatment increased insulin receptor
and restored ovulation [34].
In this study, pioglitazone induced an elevation in
serum adiponectin in PCO model rats with insulin re-
sistance, suggesting that it could partially ameliorate the
pathological status of PCO via the elevation of adiponec-
tin. The effect of pioglitazone is not due to reduction of
fatty tissue, but seems to be a direct action on PPAR-γ
because the treatment did not affect the body weight of
the rats.
Conclusions
Pioglitazone treatment is well known to be useful for the
anovulation of PCOS patients as noted in a meta-
analysis. Unfortunately, the mechanisms for the useful-
ness of pioglitazone have not hitherto been elucidated.
In this study, pioglitazone treatment of PCO model rats
reduced the total number and rate of atretic follicles,
and also reduced their serum AMH and elevated adipo-
nectin levels. These effects appear to support the useful-
ness of pioglitazone treatment for PCOS with insulin
resistance.
Abbreviations
AMH: Anti-mullerian hormone; PCO: Polycystic ovary; PCOS: Polycystic ovary
syndrome; TNNEL: Tdt-mediated dUTP nick end labeling
Acknowledgments
This study was supported by a Grant-in-Aid for Japan Society for the Promotion
of Scinence (C) 25462568 of the Ministry of Education, Science and Culture of
Japan (to TE).
Availability of data and materials
Availability of data and materials in journal of Ovarian Research were
accepted by the authors.
Authors’ contributions
MM participated in the design and performance of the experiments, analysis
and interpretation of the data, and drafting the manuscript. TE conceived
the project, designed experiments and revised the manuscript. TB supervised
the animal studies and contributed to the preparation of the manuscript. YK
involved in data analysis. KI also involved in data analysis. TK also involved in
data analysis. HH was involved in the conception and design of the study. TS
was involved in the conception of the study, reviewed the manuscript, and
approved the final draft. All authors read and approved the final manuscript.
Ethics approval
Animals used in this study were maintained in accordance with the
guidelines of the Animal Resources Center of the Sapporo Medical University





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Obstetrics and Gynecology, School of Medicine, Sapporo
Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8543, Japan. 2Ena
Ladies Clinic, South 9-1, Hanakawa, Isikari 061-3209, Japan. 3Sapporo ART
Clinic, North 7 West 4, Kita-ku, Sapporo 060-0807, Japan.
Received: 1 December 2017 Accepted: 8 March 2018
References
1. Honnma H, Endo T, Kiya T, Shimizu A, Nagasawa K, Baba T, Fujimoto T,
Henmi H, Kitajima Y, Manase K, Ishioka S, Ito E, Saito T. Remarkable features
of ovarian morphology and reproductive hormones in insulin-resistant
Zucker fatty (fa/fa) rats. Reprod Biol Endocrinol. 2010;8:73.
2. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma
agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205–15.
3. Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of
pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro
fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril.
2010;94:236–41.
4. Du Q, Yang S, Wang YJ, Wu B, Zhao YY, Fan B. Thiazolidinediones on
polycystic ovary syndrome: a meta-analysis of randomized placebo-
controlled trials. Adv Ther. 2012;29:763–74.
5. Koo YA, Shin SY, Yoon BK, Choi D. Pioglitazone for teating polycystic ovary
syndrome in non-obese women of reproductive age different clinical
presentations. Gyneocl Endocrinol. 2007;23:461–7.
6. Ota H, Goto T, Yoshida T, Ohyama N. Successful pregnancies treated with
pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril.
2008;90:709–13.
7. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K,
Chang P, Poretsky L. Direct thazolidinedione action in the human ovary:
insulin-independent and insulin-sensitizing effects on steroidogenesis and
insulin-like growth factor binding protein-1 production. J Clin Endocrinol
Metab. 2005;90:6099–105.
8. Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and
metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol
Obstet. 2017;296:661–77.
9. Iwahashi H, Kuriyama H, Ouchi H, Maeda K, Nishida M, Kihara S, Sakai N,
Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita
S, Hanafusa T. Matsuzawa y: plasma cocentrations of a novel, adipose-
Morishita et al. Journal of Ovarian Research  (2018) 11:24 Page 7 of 8
specific protein, adiponectin, in type 2 diabetic patients. Arterioscler
Thromb Vasc Biol. 2000;20:1595–9.
10. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond.
Horm Metab Res. 2002;34:469–74.
11. Matsubara M, Maruoka S, katayose S. Decreased plasma adiponectin
concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;
87:2764–9.
12. Kazumi T, Kawaguchi A, Sakai K, Hiarano T, Yoshino G. Young men with
high-normal blood pressure have lower serum adiponectin, smaller LDL
size, and higher elevated heart rate than those with optimal blood pressure.
Diabetes Care. 2002;25:971–6.
13. Arita Y, Kihar S, Ouchi NO, Takahashi M, Maeda K, Miyagawa J, Hotta K,
Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S,
Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y.
Paradoxical decrease of an dipose-specific protein, adiponectin, in obesity.
Biochem Biophys Res Commun. 1999;257:79–83.
14. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni
PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association
with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;
86:1930–5.
15. Lin LY, Lin CY, Su TC, Liau CS. Angiotensin II-induced apoptosis in human
endothelial cell is inhibited by adiponectin through restoration of the
association between endothelial nitric oxide synthase and heat shock
protein 90. FEBS Lett. 2004;574:106–10.
16. Oana F, Takeda H, Hayakawa K, Matsuzawa A, Akahane S, Isaji M, Akahane
M. Physiological difference between obese (fa/fa) Zucker rats and lean
Zucker rats concerning adiponectin. Metabolism. 2005;54:995–1001.
17. Caminos JE, Nogueiras R, Gaytan F, Pineda R, Gonzalez CR, Barreiro ML,
Castano JP, Malagon MM, Pinilla L, Toppari J, Dieguez C, Tena-Sempere M.
Novel expression and direct effects of adiponectin in the rat testis.
Endocrinology. 2008;149:3390–402.
18. Chabrolle C, Tosca L, Dupont J. Regulation of adiponectin and its receptors
in rat ovary by human chorionic gonadogrophin treatment and potential
involvement of adiponectin in granulosa cell steroidogenesis. Reproduction.
2007;133:719–31.
19. Chabrolle C, Jeanpierre E, Tosca L, Rame C, Dupont J. Effects of high levels
of glucose on the steroidogenesis and the expression of adiponectin
receptors in rat ovarian cells. Reprod Biol Endocrinol. 2008;6:11.
20. Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin
in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol.
2008;284:38–45.
21. Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary
syndrome: a mountain too high? Reproduction. 2010;139:825–33.
22. Marin Bivens CL, Olster DH. Abnormal estrous cyclicity and behavioral
hyporesponsiveness to ovarian hormones in genetically obese Zucker
female rats. Endocrinology. 1997;138:143–8.
23. Hamm ML, Bhat GK, Thompson WE, Mann DR. Folliculogenesis is impaired
and granulosa cell apoptosis is increased in leptin-deficient mice. Biol
Reprod. 2004;71:66–72.
24. Singh A, Bora P, Krishna A. Direct action of adiponectin ameliorates
increased androgen synthesis and reduces insulin receptor expression in
the polycystic ovary. Biochem Biophs Res Commun. 2017;488:509–15.
25. Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary:
further evidence for a link between obesity and hyperandrogenism in
polycystic ovary syndrome. PLoS One. 2013;8:e80416.
26. Froment P, Gizard F, Staels B, Dupont J, Monget P. A role of PPARgamma in
reproduction? Med Sci (Paris). 2005;21:507–11.
27. Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen
profile in underweight women with polycystic ovary syndrome. Arc Gynecol
Obstet. 2017;296:363–71.
28. Doganay M, Ozyer SS, Var T, Tonguc E, Gun Eryilmaz O, Ozer I, Guzel AI.
Associations between adipocyte fatty acid-binding protein and clinical
parameters in polycystic ovary syndrome. Arc Gynecol Obstet. 2015;291:
447–50.
29. Schoppee PD, Garmery JC, Veldhuis JD. Putative activation of the
peroxisome proliferator-activated receptor gamma impairs androgen and
enhances progesterone biosynthesis in primary cultures of porcine theca
cells. Biol Reprod. 2002;66:190–8.
30. Carmiana E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombrdi G,
Lobo RA. Evidence for altered adipocyte function in polycystic ovary
syndrome. Eur J Endocrinol. 2005;152:389–94.
31. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F,
Sanchon R, Luque-Ramirez M, San Millan JL. Adiponectin and resistin in
PCOS: a clinical biochemical and molecular genetic study. Hum Reprod.
2006;21:2257–65.
32. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-
Tupikowska G, Demissie M. Plasma cytokines in obese women with
polycystic ovary syndrome, before and after metformin treatment. Gynecol
Endocrinol. 2008;24:378–84.
33. Campos DB, Palin MF, Bordignon V, Murphy BD. The beneficial adipokines in
reproduction and fertility. Int J obes (Lond). 2008;32:223–31.
34. Singh A, Bora P, Krishna A. Systemic adiponectin treatment reverses
polycystic ovary syndrome-like features in an animal model. Reprod Fertil
Dev. 2017;10:1071/RD17255. [Epub ahead of Print]
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Morishita et al. Journal of Ovarian Research  (2018) 11:24 Page 8 of 8
